FWM
LCTX icon

Focused Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Focused Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8
Closed -$9 – 608
2023
Q4 		$9 Hold
8
– – ﹤0.01% 1012
2023
Q3 		$9 Hold
8
– – ﹤0.01% 1021
2023
Q2 		$11 Hold
8
– – ﹤0.01% 1055
2023
Q1 		$12 Hold
8
– – ﹤0.01% 1034
2022
Q4 		$9 Hold
8
– – ﹤0.01% 1077
2022
Q3 		$0 Hold
8
– – ﹤0.01% 1001
2022
Q2 		$0 Hold
8
– – ﹤0.01% 1002
2022
Q1 		$0 Hold
8
– – ﹤0.01% 1047
2021
Q4 		$0 Hold
8
– – ﹤0.01% 1048
2021
Q3 		$0 Hold
8
– – ﹤0.01% 1052
2021
Q2 		$0 Hold
8
– – ﹤0.01% 986
2021
Q1 		$0 Hold
8
– – ﹤0.01% 960
2020
Q4 		$0 Hold
8
– – ﹤0.01% 865
2020
Q3 		$0 Hold
8
– – ﹤0.01% 823
2020
Q2 		$0 Hold
8
– – ﹤0.01% 795
2020
Q1 		$0 Hold
8
– – ﹤0.01% 744
2019
Q4 		$0 Hold
8
– – ﹤0.01% 746
2019
Q3 		$0 Hold
8
– – ﹤0.01% 745
2019
Q2 		$0 Hold
8
– – ﹤0.01% 771
2019
Q1 		$0 Buy
+8
New +$10 ﹤0.01% 736

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Focused Wealth Management's LCTX Position: Q1 2024 in Review

Focused Wealth Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2024, closing a stake of 8 shares — an estimated $9 sold.

Focused Wealth Management first reported a position in LCTX in Q1 2019 and held it in 20 quarters. The position peaked at $12 in Q1 2023. 116 funds tracked by Wall St. Rank hold LCTX as of Q1 2024.

  • Focused Wealth Management reported no remaining Lineage Cell Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 8 Lineage Cell Therapeutics shares in Q1 2024, an estimated $9.
  • Focused Wealth Management first reported a position in Lineage Cell Therapeutics in Q1 2019 and held it in 20 quarters.
  • Focused Wealth Management's Lineage Cell Therapeutics position peaked at $12 in Q1 2023.
  • 116 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.